202 related articles for article (PubMed ID: 31432469)
1. Population Pharmacokinetics of Apalutamide and its Active Metabolite N-Desmethyl-Apalutamide in Healthy and Castration-Resistant Prostate Cancer Subjects.
Pérez-Ruixo C; Pérez-Blanco JS; Chien C; Yu M; Ouellet D; Pérez-Ruixo JJ; Ackaert O
Clin Pharmacokinet; 2020 Feb; 59(2):229-244. PubMed ID: 31432469
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer.
Perez-Ruixo C; Ackaert O; Ouellet D; Chien C; Uemura H; Olmos D; Mainwaring P; Lee JY; Yu MK; Perez-Ruixo JJ; Smith MR; Small EJ
Clin Cancer Res; 2020 Sep; 26(17):4460-4467. PubMed ID: 32561663
[TBL] [Abstract][Full Text] [Related]
3. An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
Tsuchiya T; Imanaka K; Iwaki Y; Oyama R; Hashine K; Yamaguchi A; Uemura H
Int J Clin Oncol; 2019 Dec; 24(12):1596-1604. PubMed ID: 31446511
[TBL] [Abstract][Full Text] [Related]
4. An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer.
Belderbos BPSI; de Wit R; Chien C; Mitselos A; Hellemans P; Jiao J; Yu MK; Attard G; Bulat I; Edenfield WJ; Saad F
Cancer Chemother Pharmacol; 2018 Sep; 82(3):457-468. PubMed ID: 29974203
[TBL] [Abstract][Full Text] [Related]
5. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
[TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.
Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN;
Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients.
Joulia ML; Carton E; Jouinot A; Allard M; Huillard O; Khoudour N; Peyromaure M; Zerbib M; Schoemann AT; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Clin Genitourin Cancer; 2020 Apr; 18(2):155-160. PubMed ID: 31630979
[TBL] [Abstract][Full Text] [Related]
8. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.
Small EJ; Saad F; Chowdhury S; Oudard S; Hadaschik BA; Graff JN; Olmos D; Mainwaring PN; Lee JY; Uemura H; De Porre P; Smith AA; Zhang K; Lopez-Gitlitz A; Smith MR
Ann Oncol; 2019 Nov; 30(11):1813-1820. PubMed ID: 31560066
[TBL] [Abstract][Full Text] [Related]
9. Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Ladouceur M; Behl AS; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2020 Jan; 37(1):501-511. PubMed ID: 31813086
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study.
T'jollyn H; Ackaert O; Chien C; Lopez-Gitlitz A; McCarthy S; Ruixo CP; Karsh L; Chi K; Chowdhury S; Ruixo JP; Agarwal N
Cancer Chemother Pharmacol; 2022 May; 89(5):629-641. PubMed ID: 35366072
[TBL] [Abstract][Full Text] [Related]
11. Apalutamide for the treatment of metastatic castration-sensitive prostate cancer.
Dror CM; Chi KN
Future Oncol; 2020 Dec; 16(35):2905-2916. PubMed ID: 32885994
[TBL] [Abstract][Full Text] [Related]
12. Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
Al-Salama ZT
Drugs; 2019 Sep; 79(14):1591-1598. PubMed ID: 31489589
[TBL] [Abstract][Full Text] [Related]
13. Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer.
Chowdhury S; Oudard S; Uemura H; Joniau S; Pilon D; Lefebvre P; McQuarrie K; Liu J; Dearden L; Sermon J; Van Sanden S; Diels J; Hadaschik BA
Adv Ther; 2020 Jan; 37(1):512-526. PubMed ID: 31813087
[TBL] [Abstract][Full Text] [Related]
14. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.
Chi KN; Chowdhury S; Bjartell A; Chung BH; Pereira de Santana Gomes AJ; Given R; Juárez A; Merseburger AS; Özgüroğlu M; Uemura H; Ye D; Brookman-May S; Mundle SD; McCarthy SA; Larsen JS; Sun W; Bevans KB; Zhang K; Bandyopadhyay N; Agarwal N
J Clin Oncol; 2021 Jul; 39(20):2294-2303. PubMed ID: 33914595
[TBL] [Abstract][Full Text] [Related]
15. Apalutamide for the treatment of prostate cancer.
Rathkopf DE; Scher HI
Expert Rev Anticancer Ther; 2018 Sep; 18(9):823-836. PubMed ID: 30101644
[TBL] [Abstract][Full Text] [Related]
16. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
Rathkopf DE; Smith MR; Ryan CJ; Berry WR; Shore ND; Liu G; Higano CS; Alumkal JJ; Hauke R; Tutrone RF; Saleh M; Chow Maneval E; Thomas S; Ricci DS; Yu MK; de Boer CJ; Trinh A; Kheoh T; Bandekar R; Scher HI; Antonarakis ES
Ann Oncol; 2017 Sep; 28(9):2264-2271. PubMed ID: 28633425
[TBL] [Abstract][Full Text] [Related]
18. Apalutamide: A Review in Metastatic Castration-Sensitive Prostate Cancer.
Hoy SM
Drugs; 2020 Oct; 80(15):1579-1585. PubMed ID: 32930958
[TBL] [Abstract][Full Text] [Related]
19. Apalutamide and its use in the treatment of prostate cancer.
Borno HT; Small EJ
Future Oncol; 2019 Feb; 15(6):591-599. PubMed ID: 30426794
[TBL] [Abstract][Full Text] [Related]
20. Apalutamide: A new agent in the management of prostate cancer.
May MB; Glode AE
J Oncol Pharm Pract; 2019 Dec; 25(8):1968-1978. PubMed ID: 31359832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
